INmune Bio Inc. - INMB STOCK NEWS

INmune Bio Inc. (NASDAQ: INMB) presented important findings at The 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany. The data shows that XPro™, by neutralizing soluble TNF, promotes remyelination in the cuprizone model by increasing astrocyte and microglia activation responses.

Key findings include:

• Astrocytes are rapidly activated in response to demyelination
• Preventing soluble TNF and TNFR1 function in mice mirrors XPro™'s effects
• Traditional biomarkers of astroglial and microglial activation (GFAP and Iba1) are increased in myelin-promoting glial cells

These results challenge the current belief that decreased glial activation is required for remyelination, suggesting that immunosuppressive therapies may not aid brain repair in neurologic diseases.

INmune Bio Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Mark Lowdell, Ph.D., will deliver the opening plenary lecture at the International Society of Cell and Gene Therapy (ISCT) in Paris on May 31st. The talk, titled 'The Future of Immune Effector Cell Therapies for Cancer, Tumor-Primed Memory NK Cells – from Heresy to Clinical Trials,' will focus on INKmune™, the company's proprietary Natural Killer (NK) cell platform.

Dr. Lowdell's team has discovered that INKmune™ primes NK cells to a unique cancer-killing population of memory-like NK cells, differing from cytokine-primed NK cells. This breakthrough could potentially avoid complications associated with cytokine therapy. The company recently received FDA acceptance of its Investigational New Drug Application (IND) for treating metastatic castrate-resistant prostate cancer, with a Phase I/II study set to begin enrolling patients in the US later this year.

INmune Bio, Inc. (NASDAQ: INMB) will host a conference call on May 3, 2023 at 4:30 PM ET to discuss first-quarter results ending March 31, 2023 and provide a corporate update. Participants can join by dialing 1-844-826-3035 for U.S. and 1-412-317-5195 for international calls. The conference ID is 10177985. A live audio webcast will also be available. A transcript will be provided 24 hours after the call, with a replay option available until May 10, 2023.

INmune Bio focuses on developing treatments leveraging the innate immune system for diseases such as cancer and Alzheimer's. Its key platforms involve ongoing clinical trials for novel therapies, including INB03™ and XPro™, highlighting its innovative approach in precision medicine.

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced promising pre-clinical data indicating that its compound XPro™ can prevent Alzheimer’s Disease (AD) related amyloid pathology following Traumatic Brain Injury (TBI). The research, led by Kirsty J. Dixon from Virginia Commonwealth University, shows that soluble TNF contributes to amyloid development post-TBI. Treatment with XPro™ one hour after TBI effectively neutralizes soluble TNF and prevents amyloid formation, suggesting potential for early intervention in preventing AD, particularly in the elderly, who are most at risk from TBI. The findings were presented at the AD/PD™ 2023 conference on April 1, 2023. XPro™ is a next-generation TNF inhibitor showing potential in treating neurologic diseases by reducing neuroinflammation.

INmune Bio, Inc. (NASDAQ: INMB) has presented significant findings at the American Association of Cancer Research Annual Meeting 2023 regarding INB03, a dominant-negative TNF inhibitor. Targeting high-risk MUC4 expressing HER2+ and triple-negative breast cancer, INB03 reverses resistance mechanisms to immunotherapy. MUC4 presence correlates with poor survival and treatment resistance, intensifying metastatic potential. INB03 decreases MUC4 expression and enhances the effectiveness of trastuzumab-based therapies. Additionally, the Phase I trial of INB03 reported it as safe and well-tolerated, with no dose-limiting toxicity. The company plans to initiate a Phase II trial, signifying a critical step in developing more effective treatment combinations.

INmune Bio (NASDAQ: INMB) has submitted an Investigational New Drug (IND) application to the FDA for its INKmune™ therapy aimed at treating metastatic castration-resistant prostate cancer (mCRPC). This trial, involving approximately 30 patients across multiple medical centers, focuses on assessing safety and determining the optimal dosage. The therapy seeks to convert patients' NK cells into cancer-fighting memory-like NK cells. Additionally, initial data from ongoing trials shows promising tumor-killing memory-like NK cells in patients without adverse side effects. The company emphasizes the potential of INKmune™ as a viable alternative to traditional chemotherapy.

INmune Bio, Inc. (NASDAQ: INMB) announced its financial results for the year ended December 31, 2022. The company reported a net loss of approximately $27.3 million, down from $30.3 million in 2021. R&D expenses were $17.1 million, a decrease from $20.5 million year-over-year. The firm highlighted advancements in its DN-TNF platform, merging trial efforts for Mild Cognitive Impairment and Alzheimer's Disease. It also received about $6.4 million in R&D rebates to enhance patient enrollment. The FDA review regarding a clinical hold on XPro™ AD trial is ongoing, with a Phase 2 trial anticipated to begin upon resolution. Cash reserves as of December 31, 2022, stood at $52.2 million.